Ekso Bionics(TM) CEO Nathan Harding Interview on CNBC's Closing Bell Rescheduled

By GlobeNewswire,  August 04, 2014, 01:23:00 PM EDT


RICHMOND, Calif., Aug. 4, 2014 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO) a robotic exoskeleton company, today announced that, due to a breaking announcement from President Obama, CEO Nathan Harding's interview will be rescheduled to a later date.

About Ekso Bionics

Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.

Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. To learn more about Ekso Bionics please visit us at www.eksobionics.com

Facebook: www.facebook.com/eksobionics

Twitter: @eksobionics

YouTube: http://www.youtube.com/user/EksoBionics/

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's Current Report on Form 8-K/A filed on March 31, 2014 and the Company's latest Form 10-Q filed on May 13, 2014. The Company does not undertake to update these forward-looking statements.

CONTACT: Media Contact:
         Heidi Darling, Marketing Manager
         Phone: 415.302.4777
         hdarling@eksobionics.com

         Investor Contact:
         Lauren Glaser, Vice President
         Phone: 646.378.2972
         lglaser@troutgroup.com
Source: Ekso Bionics

This article appears in: News Headlines

Referenced Stocks: EKSO


Latest News Video

No Charges in Rumney Death
No Charges in Rumney Death          




Most Active by Volume

Company Last Sale Change Net / %
AAPL $ 102.47 2.71 ▲ 2.72%
BAC $ 16.60 0.34 ▲ 2.09%
PBR $ 13.20 0.80 ▼ 5.71%
KO $ 40.68 2.61 ▼ 6.03%
QQQ $ 96.87 2.48 ▲ 2.63%
RF $ 9.26 0.10 ▲ 1.09%
MU $ 31.19 1.50 ▲ 5.05%
PFE $ 28.28 0.35 ▲ 1.25%

As of 10/21/2014, 04:15 PM